ENPP2 and idiopathic pulmonary fibrosis: Currently, the orally active non-competitive ATX inhibitor cudetaxestat (BLD-0409, compound 10, Table 1), which binds in the ATX tunnel, is in a phase II clinical trial for the treatment of IPF (NCT05373914) [36,37].